First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company has recently completed enrollment in a Phase 2 clinical trial for COVID-GI infection, is advancing a Phase 2 study in ulcerative colitis-proctitis, and preparing to initiate a Phase 2 trial for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies – niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company has recently completed enrollment in a Phase 2 clinical trial for COVID-GI infection, is advancing a Phase 2 study in ulcerative colitis-proctitis, and preparing to initiate a Phase 2 trial for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.
Ticker:
FWBI
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Niclosamide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
